GlassScriptPhysician profile
Timothy J Snodgrass
NPI 1962484055
$3,019.96
in general payments reported to CMS, 2019-2025
29 companies · $847 in 2025
The $847 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $12.53 · 2021: $329 · 2022: $554 · 2023: $610 · 2024: $563 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $257.72 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $195.74 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.23 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.63 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $131.70 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $126.15 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $121.21 | 2023-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.45 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $89.43 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $84.49 | 2021-2023 | Rexulti |
| Pfizer INC. | $75.40 | 2023-2024 | |
| Axsome Therapeutics, INC. | $72.67 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $72.41 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $68.77 | 2021-2024 | Airsupra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $62.27 | 2022-2023 | Accrufer |
| Bausch Health US, LLC | $61.32 | 2022 | |
| Xeris Pharmaceuticals, INC. | $56.98 | 2024-2025 | Gvoke Hypopen |
| Verona Pharma, INC. | $46.84 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $35.53 | 2019 | |
| Inspire Medical Systems, INC. | $28.99 | 2025 | Inspire |
| Vapotherm INC | $21.44 | 2022 | |
| Sumitomo Pharma America, INC. | $19.61 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $16.94 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.92 | 2023 | Horizant |
| Paratek Pharmaceuticals, INC. | $14.15 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $13.90 | 2022 | |
| Genentech USA, INC. | $13.80 | 2022 | |
| Sanofi Pasteur INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.